Oakwood Capital Management LLC CA lowered its position in Merck & Company, Inc. (NYSE:MRK) by 4.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 94,062 shares of the company’s stock after selling 4,199 shares during the quarter. Merck & comprises about 1.5% of Oakwood Capital Management LLC CA’s portfolio, making the stock its 22nd largest position. Oakwood Capital Management LLC CA’s holdings in Merck & were worth $6,028,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Vigilant Capital Management LLC boosted its holdings in Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after acquiring an additional 250 shares during the period. Cascade Investment Advisors Inc. grew its position in Merck & by 15.5% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the last quarter. Harbour Capital Advisors LLC bought a new position in Merck & in the 1st quarter valued at $127,000. Mascoma Wealth Management LLC grew its position in Merck & by 8.2% in the 2nd quarter. Mascoma Wealth Management LLC now owns 2,474 shares of the company’s stock valued at $159,000 after acquiring an additional 187 shares during the last quarter. Finally, Gradient Investments LLC grew its position in Merck & by 17.5% in the 2nd quarter. Gradient Investments LLC now owns 2,710 shares of the company’s stock valued at $174,000 after acquiring an additional 404 shares during the last quarter. Hedge funds and other institutional investors own 72.92% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/10/04/merck-company-inc-mrk-stake-decreased-by-oakwood-capital-management-llc-ca.html.

Shares of Merck & Company, Inc. (MRK) opened at 64.37 on Wednesday. The company’s 50-day moving average price is $64.08 and its 200-day moving average price is $63.67. The company has a market cap of $175.56 billion, a P/E ratio of 34.85 and a beta of 0.80. Merck & Company, Inc. has a 12 month low of $58.29 and a 12 month high of $66.80.

Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the firm earned $0.93 earnings per share. Equities analysts forecast that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Thursday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.92%. Merck &’s payout ratio is 76.11%.

A number of research firms have weighed in on MRK. BMO Capital Markets reiterated a “buy” rating and issued a $74.00 target price on shares of Merck & in a research note on Tuesday, June 6th. Credit Suisse Group set a $72.00 target price on shares of Merck & and gave the company a “buy” rating in a research note on Tuesday, June 6th. Zacks Investment Research lowered shares of Merck & from a “buy” rating to a “hold” rating in a research note on Monday, June 12th. BidaskClub upgraded shares of Merck & from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Citigroup Inc. set a $65.00 price target on shares of Merck & and gave the stock a “hold” rating in a report on Wednesday, July 5th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $70.00.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.